BEDFORD, Mass.--(BUSINESS WIRE)--Mar. 28, 2016--
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company
focused on the development and commercialization of innovative therapies
for diseases and conditions of the eye, today announced that the Company
will host an Investor Day on Wednesday, April 6, 2016 at 12:00 p.m. ET
in New York, NY. The Company will be joined by several leading cataract,
glaucoma, and retina specialists.
The live audio webcast and accompanying slide presentation can be
accessed through the Calendar of Events section of the Company's website
at investors.ocutx.com. A replay of the webcast will be available on the
Company's website for two weeks following the event.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical company
focused on the development and commercialization of innovative therapies
for diseases and conditions of the eye using its proprietary hydrogel
platform technology. Ocular Therapeutix's lead product candidate,
DEXTENZA™ (sustained release dexamethasone) Intracanalicular Depot, is
in Phase 3 clinical development for post-surgical ocular inflammation
and pain and allergic conjunctivitis, and in Phase 2 clinical
development for inflammatory dry eye disease. An NDA for the
post-operative ocular pain indication has been accepted for filing by
the FDA with a PDUFA date of July 24, 2016. A third Phase 3 clinical
trial is being conducted for post-operative ocular inflammation and
pain. For glaucoma and ocular hypertension, a Phase 2b clinical trial
has been completed with OTX-TP (sustained release travoprost)
Intracanalicular Depot, and the first of two OTX-TP Phase 3 clinical
trials is expected to be initiated in the third quarter of 2016. Ocular
Therapeutix is also evaluating sustained-release injectable anti-VEGF
drug depots for back-of-the-eye diseases. Ocular Therapeutix's first
product, ReSure® Sealant, is FDA-approved to seal corneal incisions
following cataract surgery.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160328005634/en/
Source: Ocular Therapeutix, Inc.
Investors
Ocular Therapeutix, Inc.
Brad Smith
Chief
Financial Officer
bsmith@ocutx.com
or
Burns
McClellan on behalf of Ocular Therapeutix
Steve Klass, 212-213-0006
sklass@burnsmc.com
or
Media
Ocular
Therapeutix, Inc.
Scott Corning
Vice President of Sales and
Marketing
scorning@ocutx.com
